Refractory Metastatic Colorectal Cancer clinical trials

Explore recruiting refractory metastatic colorectal cancer clinical trials.

Recruiting refractory metastatic colorectal cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Refractory Metastatic Colorectal Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

AndroMETa-CRC-560: An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal Cancer

Greece, Portugal, Germany, Belgium, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Open-label, Phase 2 study of Botensilimab (AGEN1181) as Monotherapy and in Combination with Balstilimab (AGEN2034) or Investigator’s Choice Standard of Care (Regorafenib or Trifluridine and Tipiracil) for the Treatment of Refractory Metastatic Colorectal Cancer

Italy, France, Belgium, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II trial of Pembrolizumab and Olaparib in homologous-recombination deficient (HRD) advanced colorectal cancer (CRC).

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment with Melphalan/HDS Followed by Consolidation Treatment with Trifluridine–tipiracil plus Bevacizumab Versus Trifluridine–tipiracil plus Bevacizumab Alone in Patients with Refractory Metastatic Colorectal Cancer with Liver Dominant Disease

Spain, Germany, Czechia, Italy, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff

Germany, Poland, France, Italy, Netherlands, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Refractory Metastatic Colorectal Cancer trials by city

Refractory Metastatic Colorectal Cancer in Toronto Refractory Metastatic Colorectal Cancer in Vancouver Refractory Metastatic Colorectal Cancer in Montreal Refractory Metastatic Colorectal Cancer in Calgary Refractory Metastatic Colorectal Cancer in Edmonton Refractory Metastatic Colorectal Cancer in Ottawa Refractory Metastatic Colorectal Cancer in Winnipeg Refractory Metastatic Colorectal Cancer in Quebec City Refractory Metastatic Colorectal Cancer in Hamilton Refractory Metastatic Colorectal Cancer in Kitchener Refractory Metastatic Colorectal Cancer in London Refractory Metastatic Colorectal Cancer in Halifax Refractory Metastatic Colorectal Cancer in New York Refractory Metastatic Colorectal Cancer in Los Angeles Refractory Metastatic Colorectal Cancer in Chicago Refractory Metastatic Colorectal Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease